No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IOBT IO Biotech
- 1.420
- -0.030-2.07%
Close Apr 26 16:00 ET
- 1.370
- -0.050-3.52%
Post 16:29 ET
93.55MMarket Cap-717P/E (TTM)
1.540High1.400Low73.38KVolume1.430Open1.450Pre Close104.68KTurnover0.28%Turnover RatioLossP/E (Static)65.88MShares2.64052wk High0.70P/B36.89MFloat Cap0.81652wk Low--Dividend TTM25.98MShs Float17.880Historical High--Div YieldTTM9.66%Amplitude0.816Historical Low1.426Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
IO Biotech Board Member Jack Nielsen Resigns Due to Health
IO Biotech Presents New Data For Cancer Vaccine Candidate, IO102-IO103, At AACR 2024
IO Biotech Presents New Data For Cancer Vaccine Candidate, IO102-IO103, At AACR 2024
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech (Nasdaq: IOBT) today shared new data related to the company's lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
IO Biotech: Miyara Will Be Based in the US, Reporting to CEO, Mai-Britt Zocca >IOBT
IO Biotech: Miyara Will Be Based in the US, Reporting to CEO, Mai-Britt Zocca >IOBT
IO Biotech Appoints Faical Miyara Chief Business Officer >IOBT
IO Biotech Appoints Faical Miyara Chief Business Officer >IOBT
IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg